Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]


Angiogenesis is a physiological process by which new blood vessels are formed from pre-existing blood vessels. It is vital for normal growth and development, wound healing, skeletal muscle hypertrophy as well as maintenance of menstruation and pregnancy in women. Apart from the physiological role it plays, angiogenesis also contributes to pathological conditions such as cancer and cardiovascular diseases.

The mechanism of angiogenesis is tightly regulated at the cellular level with the release of pro-angiogenic and anti-angiogenic growth factors and proteins. However, in disease pathology, ‘angiogenic switch’ is a key step where the balance between the pro-angiogenic and anti-angiogenic factors is altered resulting in increased or decreased vascularization. Aberrant angiogenesis plays a key role in cancer progression and neovascularization is necessary for sustained tumor growth and metastasis. During tumorigenesis, hypoxia induced stabilization of HIF-1α transcription factor leads to the binding of HIF-1α to HIF-1ß, which upregulates the expression of several pro-angiogenic factors such as VEGF. VEGF binds to its receptor, VEGFR on the endothelial cells triggering a number of signaling cascades such as Notch, PI3K/Akt, Erk1/2 and Smad pathways leading to the migration and differentiation of endothelial cells. VEGF and VEGF receptors are widely recognized as critical factors responsible for vascularization and hence, their mechanism of action is of great interest in the development of therapeutic inhibitors. In addition to cancer, there is substantial interest in harnessing angiogenesis as a therapeutic target in cardiovascular diseases as well. Research has shown a close association between angiogenesis and production of vulnerable plaques in atherosclerosis, leading to reduced blood flow to tissues. In this context, therapeutic angiogenesis aims to induce, augment and control angiogenic responses to re-vascularize ischemic tissues.

BioVision is proud to offer a vast array of popular and widely studied angiogenesis targets. Our angiogenesis portfolio is divided into five major product categories, namely Assay Kits, ELISA Kits, Proteins, Antibodies and Angiogenesis Inhibitors. These products have applications in areas of research including but not limited to Angiogenesis, Cancer, Cardiovascular Diseases and Metabolism.

Angiogenesis Categories